Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Brovana"

11 News Found

Cipla receives final approval for generic version of Brovana
News | June 24, 2021

Cipla receives final approval for generic version of Brovana

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana


Lupin launches generic version of Brovana in US
News | June 04, 2021

Lupin launches generic version of Brovana in US

Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction


Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi
News | December 23, 2023

Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi

The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired


Lupin to acquire two inhalation brands from Sunovion for US$75 million
News | October 20, 2022

Lupin to acquire two inhalation brands from Sunovion for US$75 million

The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.


Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
News | August 09, 2022

Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher

Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.


Alembic Pharmaceuticals receives USFDA  approval for Arformoterol Tartrate
Drug Approval | May 11, 2022

Alembic Pharmaceuticals receives USFDA approval for Arformoterol Tartrate

This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies


Lupin receives approval from USFDA for Arformoterol Tartrate inhalation
Drug Approval | February 08, 2022

Lupin receives approval from USFDA for Arformoterol Tartrate inhalation

Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)


Margins under pressure; domestic market growth to slow down: Nirmal Bang
News | January 06, 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies


IPM growth led by Covid  driven products to taper off in Q2FY22: Nirmal Bang
News | October 06, 2021

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report


Lupin posts net profit of Rs 542.46 cr. in Q1FY22
News | August 11, 2021

Lupin posts net profit of Rs 542.46 cr. in Q1FY22

The profits were bolstered by the Boehringer Ingelheim MEK program income